摘要
囊性纤维化(CF)是最常见的常染色体显性遗传性疾病,白人新生儿的发病率为1/2500。CF的肺部病理与呼吸道上皮表面的脱水有关,部分是由于上皮钠通道(ENaC)对Na+过度吸收引起的。这种Na+吸收过多及其相关的囊性纤维化跨膜传导调节(CFTR)的潜在遗传缺陷的分子机制尚不完全清楚。然而,很明显,CFTR减少Cl-分泌和ENaC增强Na+的吸收导致了CF。因此,我们认为可以尝试一种双轨战略,通过重组缺陷的CFTR使Cl-的分泌增加,同时阻断ENaC防止Na+吸收过多。由于已对CFTR的克隆做了很大努力,并对减少Cl-分泌的CFTR蛋白进行了矫正。限制Na+吸收过多的正面意义,在于提供使用如ASOs或siRNA这样的小分子抑制剂分别靶向翻译和抑制ENaC的技术。本文中我们讨论了可能的CFTR/ENaC的相互作用,描述了ENaC的结构以及一些阻止相关肺纤维化病中Na+吸收过多的尝试。因此,我们进行了简短的总结,例如阿米洛利治疗方法以及用ASOS和siRNA创造性的阻塞。
关键词: 阿米洛利,ASOs,囊性纤维化,囊性纤维化跨膜电导调节因子(CFTR),ENaC,siRNA
图形摘要
Current Drug Targets
Title:Targeting ENaC as a Molecular Suspect in Cystic Fibrosis
Volume: 16 Issue: 9
Author(s): Nadine Bangel-Ruland, Katja Tomczak and Wolf-Michael Weber
Affiliation:
关键词: 阿米洛利,ASOs,囊性纤维化,囊性纤维化跨膜电导调节因子(CFTR),ENaC,siRNA
摘要: Cystic fibrosis (CF) is the most common life shortening autosomal inherited disorder, affecting 1 in 2500 newborns in the Caucasian population. In CF the lung pathology is associated with dehydration of the airways epithelial surface which in part results from Na+ hyperabsorption via the epithelial sodium channel (ENaC). The molecular mechanisms of this Na+ hyperabsorption and its correlation with the underlying genetic defect in the cystic fibrosis transmembrane conductance regulator (CFTR) are not fully understood. However, it is obvious that a reduced Cl- secretion by CFTR and an enhanced Na+ absorption through ENaC lead to the so far incurable disease. Therefore, it could be indicated to pursue a double-tracked strategy in that way enabling Cl- secretion by a reconstitution of the defect CFTR as well as blocking ENaC to prevent Na+ hyperabsorption. Since the cloning of CFTR great efforts have been done in delivery of CFTR for the correction of the reduced Cl- secretion. Positive benefits for the inhibition of the CF related Na+ hyperabsorption offer technologies using small molecule inhibitors like ASOs or siRNA, which target translation and knockdown of ENaC, respectively. In this review we discuss possible CFTR/ENaC interactions in the context of CF, describe ENaC structure as well as some of the numerous attempts that were performed to prevent the Na+ hyperabsorption in CF related lung disease. Thus, we give a short summary of e.g. amiloride therapy approaches and focus on inventive blocking efforts using ASOs and siRNA.
Export Options
About this article
Cite this article as:
Nadine Bangel-Ruland, Katja Tomczak and Wolf-Michael Weber , Targeting ENaC as a Molecular Suspect in Cystic Fibrosis, Current Drug Targets 2015; 16 (9) . https://dx.doi.org/10.2174/1389450116666141212101626
DOI https://dx.doi.org/10.2174/1389450116666141212101626 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Related Journals
Related Books
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Neurotrophic Factors - A Tool for Therapeutic Strategies in Neurological,Neuropsychiatric and Neuroimmunological Diseases?
Current Medicinal Chemistry Editorial [Hot Topic: Mitochondria as a Pharmacological Target: A Clue for Efficacy and a Reason for Toxicity (Executive Guest Editor: Nadezda Apostolova)]
Current Pharmaceutical Design Mitochondria-Targeted Drugs
Current Molecular Pharmacology Significance of P2X7 Receptor Variants to Human Health and Disease
Recent Patents on DNA & Gene Sequences Nuclear Imaging of Inflammation in Neurologic and Psychiatric Disorders
Current Clinical Pharmacology Inflammatory Cyclooxygenase Activity and PGE<sub>2</sub> Signaling in Models of Alzheimer’s Disease
Current Immunology Reviews (Discontinued) Beyond Monoamines-Novel Targets for Treatment-Resistant Depression: A Comprehensive Review
Current Neuropharmacology Glutaminase Isoenzymes as Key Regulators in Metabolic and Oxidative Stress Against Cancer
Current Molecular Medicine Functional Interactions of Tau and their Relevance for Alzheimers Disease
Current Alzheimer Research Mn (III) Tetrakis (4-Benzoic Acid) Porphyrin Protects Against Neuronal and Glial Oxidative Stress and Death After Spinal Cord Injury
CNS & Neurological Disorders - Drug Targets Molecular, Cellular and Clinical Aspects of Intracerebral Hemorrhage: Are the Enemies Within?
Current Neuropharmacology Matrix Metalloproteinase-2 and Epidermal Growth Factor are Decreased in Platelets of Alzheimer Patients
Current Alzheimer Research Neuroregeneration in Parkinson’s Disease: From Proteins to Small Molecules
Current Neuropharmacology Subcellular Injuries in Alzheimer's Disease
CNS & Neurological Disorders - Drug Targets Tryptophan Catabolites and Their Impact on Multiple Sclerosis Progression
Current Pharmaceutical Design Phase 1 Safety, Tolerability and Pharmacokinetics of 3K3A-APC in Healthy Adult Volunteers
Current Pharmaceutical Design The Concept of “Neuroprotection” in Neurological Diseases
Current Neuropharmacology Topical Delivery of Drugs for the Effective Treatment of Fungal Infections of Skin
Current Pharmaceutical Design RNA Metabolism in Neurodegenerative Disease
Current Chemical Biology Micro Arrays and Biochips: Applications and Potential in Genomics and Proteomics
Current Genomics